
    
      The protocol was originally designed as a Simon two stage but after it was determined that
      the initial 13 patients enrolled did not meet the definition of a 'responder' according to
      the International Uniform Response Criteria for multiple myeloma the protocol was amended to
      allow patients who had disease progression at any time or stable disease for 3 cycles and did
      not meet a withdrawal criterion or had withdrawn consent to have 40 mg of dexamethasone added
      to their dose of ruxolitinib.
    
  